About Akebia Therapeutics (NASDAQ:AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098
Debt
Debt-to-Equity RatioN/A
Current Ratio2.48%
Quick Ratio2.48%
Price-To-Earnings
Trailing P/E Ratio-5.24
Forward P/E Ratio-4.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.98 million
Price / Sales2.93
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book3.68
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-43.21%
Return on Equity-100.28%
Return on Assets-23.69%
Miscellaneous
Employees114
Outstanding Shares56,110,000
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc. (NASDAQ:AKBA) released its quarterly earnings data on Monday, March, 12th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.61. The biopharmaceutical company earned $87.32 million during the quarter, compared to analyst estimates of $66 million. Akebia Therapeutics had a negative return on equity of 100.28% and a negative net margin of 43.21%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
9 Wall Street analysts have issued 12-month price objectives for Akebia Therapeutics' stock. Their forecasts range from $17.00 to $30.00. On average, they expect Akebia Therapeutics' share price to reach $22.7778 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/15/2018)
- 2. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)
- 3. Aegis analysts commented, "We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA." (6/30/2017)
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), ARMO BioSciences (ARMO), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL) and Deciphera Pharmaceuticals (DCPH).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler MBA, Chief Exec. Officer, Pres and Director (Age 54)
- Mr. Jason A. Amello, Chief Financial Officer, Sr. VP and Treasurer (Age 50)
- Dr. Bradley J. Maroni M.D., Medical Advisor (Age 65)
- Ms. Theresa McNeely, Sr. VP - Corp. Communications and Investor Relations (Age 54)
- Ms. Nicole R. Hadas J.D., Sr. VP, Gen. Counsel and Sec. (Age 45)
Has Akebia Therapeutics been receiving favorable news coverage?
Press coverage about AKBA stock has been trending somewhat positive on Monday, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akebia Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $9.28.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $520.73 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akebia Therapeutics (NASDAQ:AKBA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Their average twelve-month price target is $22.7778, suggesting that the stock has a possible upside of 145.45%. The high price target for AKBA is $30.00 and the low price target for AKBA is $17.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.89 | 2.89 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.7778 | $22.7778 | $22.7778 | $22.8571 |
| Price Target Upside: | 145.45% upside | 68.47% upside | 51.35% upside | 18.86% upside |
Akebia Therapeutics (NASDAQ:AKBA) Consensus Price Target History
Akebia Therapeutics (NASDAQ:AKBA) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Akebia Therapeutics (NASDAQ:AKBA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akebia Therapeutics (NASDAQ AKBA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 60.00%
Akebia Therapeutics (NASDAQ AKBA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/15/2018 | Duane Nash | Director | Sell | 1,000 | $14.62 | $14,620.00 | |  |
| 10/2/2017 | Duane Nash | Director | Sell | 1,188 | $19.64 | $23,332.32 | | |
| 10/2/2017 | Michel Dahan | SVP | Sell | 1,398 | $19.64 | $27,456.72 | | |
| 9/28/2017 | Michel Dahan | SVP | Sell | 5,000 | $19.30 | $96,500.00 | 97,224 | |
| 8/15/2017 | Michel Dahan | SVP | Sell | 5,000 | $15.00 | $75,000.00 | 102,224 | |
| 7/5/2017 | Muneer A Satter | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | | |
| 7/3/2017 | Duane Nash | Director | Sell | 990 | $14.27 | $14,127.30 | 23,687 | |
| 7/3/2017 | Nicole R. Hadas | SVP | Sell | 1,554 | $14.26 | $22,160.04 | | |
| 4/3/2017 | Duane Nash | Director | Sell | 991 | $9.20 | $9,117.20 | 24,677 | |
| 4/3/2017 | Nicole R Hadas | SVP | Sell | 1,556 | $9.18 | $14,284.08 | 109,856 | |
| 1/3/2017 | Duane Nash | Director | Sell | 1,980 | $10.46 | $20,710.80 | 25,668 | |
| 1/1/2017 | Nicole R. Hadas | SVP | Sell | 1,810 | $10.49 | $18,986.90 | | |
| 7/6/2016 | Duane Nash | Director | Sell | 1,980 | $7.48 | $14,810.40 | 29,629 | |
| 7/5/2016 | Nicole R. Hadas | SVP | Sell | 1,557 | $7.47 | $11,630.79 | | |
| 4/4/2016 | Michel Dahan | SVP | Sell | 1,401 | $9.41 | $13,183.41 | 74,956 | |
| 10/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $8.67 | $12,866.28 | 65,260 | |
| 7/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $9.54 | $14,157.36 | | |
| 4/22/2015 | Muneer A Satter | Director | Buy | 420,000 | $8.25 | $3,465,000.00 | | |
| 4/2/2015 | Nicole R Hadas | SVP | Sell | 1,483 | $9.09 | $13,480.47 | | |
| 1/2/2015 | Nicole R Hadas | VP | Sell | 1,715 | $11.46 | $19,653.90 | | |
| 12/29/2014 | John P Butler | CEO | Buy | 1,000 | $11.57 | $11,570.00 | | |
| 12/26/2014 | Duane Nash | Director | Sell | 11,933 | $11.23 | $134,007.59 | | |
| 12/22/2014 | John P Butler | CEO | Buy | 1,000 | $11.92 | $11,920.00 | | |
| 12/15/2014 | John P Butler | CEO | Buy | 1,000 | $11.34 | $11,340.00 | | |
| 12/2/2014 | Ronald C Renaud Jr | Director | Buy | 5,000 | $11.92 | $59,600.00 | | |
| 11/26/2014 | Jason Amello | CFO | Buy | 1,000 | $13.22 | $13,220.00 | | |
| 11/25/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.18 | $65,900.00 | | |
| 11/24/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.88 | $69,400.00 | | |
| 11/21/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.73 | $73,650.00 | | |
| 11/20/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.70 | $73,500.00 | | |
| 11/19/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.85 | $74,250.00 | | |
| 11/18/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.84 | $69,200.00 | | |
| 11/17/2014 | Muneer A Satter | Director | Buy | 5,000 | $12.94 | $64,700.00 | | |
| 11/14/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.91 | $59,550.00 | | |
| 11/13/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.56 | $57,800.00 | | |
| 11/12/2014 | John P Butler | CEO | Buy | 1,000 | $10.31 | $10,310.00 | | |
| 11/12/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.90 | $59,500.00 | | |
| 3/25/2014 | A/S Novo | Insider | Buy | 182,590 | $17.00 | $3,104,030.00 | | |
| 3/25/2014 | Jason Amello | CFO | Buy | 4,000 | $17.00 | $68,000.00 | | |
| 3/25/2014 | John P Butler | CEO | Buy | 13,850 | $17.00 | $235,450.00 | | |
| 3/25/2014 | Muneer A Satter | Director | Buy | 91,295 | $17.00 | $1,552,015.00 | | |
(Data available from 1/1/2013 forward)
Akebia Therapeutics (NASDAQ AKBA) News Headlines
| Source: |
|
Akebia Therapeutics (NASDAQ:AKBA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akebia Therapeutics (NASDAQ:AKBA) Income Statement, Balance Sheet and Cash Flow Statement
Akebia Therapeutics (NASDAQ AKBA) Stock Chart for Monday, April, 23, 2018
Loading chart…
